1. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
- Author
-
Weinmann, L., Wischhusen, J., Demma, M. J., Naumann, U., Roth, P., DasMahapatra, B., and Weller, M.
- Subjects
GLIOMAS ,CELLS ,CELL death ,APOPTOSIS ,NERVOUS system tumors - Abstract
Reactivation of mutant p53 in tumours is a promising strategy for cancer therapy. Here we characterise the novel p53 rescue compound P53R3 that restores sequence-specific DNA binding of the endogenously expressed p53
R175H and p53R273H mutants in gel-shift assays. Overexpression of the paradigmatic p53 mutants p53R175H , p53R248W and p53R273H in the p53 null glioma cell line LN-308 reveals that P53R3 induces p53-dependent antiproliferative effects with much higher specificity and over a wider range of concentrations than the previously described p53 rescue drug p53 reactivation and induction of massive apoptosis (PRIMA-1). Furthermore, P53R3 enhances recruitment of endogenous p53 to several target promoters in glioma cells bearing mutant (T98G) and wild-type (LNT-229) p53 and induces mRNA expression of numerous p53 target genes in a p53-dependent manner. Interestingly, P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5 (DR5) whereas CD95 and TNF receptor 1 levels are unaffected. Accordingly, P53R3 does not sensitise for CD95 ligand- or tumour necrosis factor α-induced cell death, but displays synergy with Apo2L.0 in 9 of 12 glioma cell lines. Both DR5 surface induction and synergy with Apo2L.0 are sensitive to siRNA-mediated downregulation of p53. Thus this new p53 rescue compound may open up novel perspectives for the treatment of cancers currently considered resistant to the therapeutic induction of apoptosis.Cell Death and Differentiation (2008) 15, 718–729; doi:10.1038/sj.cdd.4402301; published online 18 January 2008 [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF